机构:[1]From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province[3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
第一作者机构:[1]From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province[3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
共同第一作者:
通讯作者:
通讯机构:[1]From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University[2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province[3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, China.
推荐引用方式(GB/T 7714):
Su Dan,Zhang Yu,Li Zhuoyuan,et al.177 Lu-DOTATATE in the Treatment of Recurrent Pheochromocytoma With Multiple Metastases[J].Clinical Nuclear Medicine.2024,49(4):338-339.doi:10.1097/RLU.0000000000004994.
APA:
Su Dan,Zhang Yu,Li Zhuoyuan,Yang Hongyu&Chen Yue.(2024).177 Lu-DOTATATE in the Treatment of Recurrent Pheochromocytoma With Multiple Metastases.Clinical Nuclear Medicine,49,(4)
MLA:
Su Dan,et al."177 Lu-DOTATATE in the Treatment of Recurrent Pheochromocytoma With Multiple Metastases".Clinical Nuclear Medicine 49..4(2024):338-339